1. Home
  2. STDN vs FTRE Comparison

STDN vs FTRE Comparison

Compare STDN & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Standard Nuclear Inc. Class A Common Stock

STDN

Standard Nuclear Inc. Class A Common Stock

SELL

Current Price

$12.48

Market Cap

1.9B

ML Signal

SELL

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

SELL

Current Price

$20.92

Market Cap

1.9B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
STDN
FTRE
Founded
2024
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.9B
IPO Year
2026
2023

Fundamental Metrics

Financial Performance
Metric
STDN
FTRE
Price
$12.48
$20.92
Analyst Decision
Strong Buy
Buy
Analyst Count
9
13
Target Price
$17.56
★ $21.04
AVG Volume (30 Days)
439.1K
★ 1.5M
Earning Date
11-20-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $2,723,400,000.00
Revenue This Year
$439.23
N/A
Revenue Next Year
$259.21
$3.19
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 1.00
52 Week Low
$7.05
$8.55
52 Week High
$17.34
$23.51

Technical Indicators

Market Signals
Indicator
STDN
FTRE
Relative Strength Index (RSI) 46.23 61.23
Support Level $11.46 $15.77
Resistance Level $13.73 $21.25
Average True Range (ATR) 0.95 1.03
MACD 0.00 0.05
Stochastic Oscillator 27.52 44.39

Price Performance

Historical Comparison
STDN
FTRE

About STDN Standard Nuclear Inc. Class A Common Stock

Standard Nuclear Inc is an independent advanced nuclear fuel company. The company designs, engineers, and manufactures advanced nuclear fuels, with a primary focus on TRISO fuel for advanced reactors. Its operations include industrial-scale TRISO fuel manufacturing and the development of fuel for advanced reactors that utilize TRISO fuel. The company operates in a single operating and reportable segment, as it is engaged in a single business activity of TRISO production. It derives revenue from fuel development and services agreements. Geographically, the maximum revenue is generated from the United States.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.

Share on Social Networks: